Neogenomics Inc.
NEO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.26B
Close$
$-11.27
165.7% downside
Current Fair Value
165.7% downsideOvervalued by 165.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.26 Billion |
|---|---|
| Enterprise Value | $2.57 Billion |
| Earnings per Share | $-0.84 |
| Beta | 1.78 |
| Outstanding Shares | 128,587,000 |
Return
| Return on Equity | -4.11% |
|---|---|
| Return on Assets | -2.39% |
| Return on Invested Capital | -2.59% |
Valuation & Multiples
| P/E Ratio | -70.42 |
|---|---|
| PEG | 97.56 |
| Price to Sales | 2.86 |
| Price to Book Ratio | 2.86 |
| Enterprise Value to Revenue | 3.26 |
| Enterprise Value to EBIT | -79.52 |
| Enterprise Value to Net Income | -80 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS Estimate
$0.06
Consensus analyst estimateRevenue Estimate
$206.70 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 16, 2027
EPS Estimate
$0.06
Consensus analyst estimateRevenue Estimate
$210.60 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 0.59% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.93%▼ 558.07% |
|---|---|
| Total Invested | $28.13M▼ 98.68% |
| Investors Holding | 68▼ 210.00% |
About Neogenomics Inc.
1,600 employees
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...